http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S59128366-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_382ccfc2ebebcaee15aa7cda4cee86bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_731a5c14521f8abac80caa8a90045c83
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
filingDate 1983-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d76607092d2cec7f8308bcceba638e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2eeb8c264321d3b886decfe046738fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c2ce1a7861549509548b18f7c220ef3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84fc5f4be2fb22d059a30b2328dc3989
publicationDate 1984-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S59128366-A
titleOfInvention Peptide relating to human leukemia virus
abstract NEW MATERIAL:The peptide of formula I W formula III (R is H or H-Tyr). n USE: Diagnosis and research of mature T-cell leukemia such as adult T-cell leukemia, T-cell lymphosarcoma cutis, etc., lymphoma, and relating diseases. n PROCESS: The peptide can be prepared according to peptide synthesis process, by condensing the amino acids one by one to the terminal amino acid by acid proccess, chloride process, acid anhydride process, etc. or by coupling the amino acids in several fragments. For example, in the case of solid phase synthesis, the C-terminated amino acid is bonded to an insoluble carrier (e.g. chloromethylated resin) through its carboxyl group, the amino-protecting group is removed, the amino-protected amino acids are bonded by condensation reaction according to the amino acid sequences of formulas I WIII, the peptide is removed from the insoluble carrier after the completion of the synthesis of whole sequence, and if necessary, the protecting groups are removed. n COPYRIGHT: (C)1984,JPO&Japio
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6242174-B1
priorityDate 1983-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID312
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559517

Total number of triples: 31.